GT Biopharma (GTBP) Other Non-Current Assets (2014 - 2023)
GT Biopharma (GTBP) posted quarterly Other Non-Current Assets of $9000.0 for Q3 2023, little changed year-over-year from $9000.0 in Q3 2022, and little changed quarter-over-quarter from $9000.0 in Q2 2023.
GT Biopharma (GTBP) Other Non-Current Assets (2014 - 2023) Analysis & Trends
GT Biopharma (GTBP) has reported Other Non-Current Assets for 7 consecutive years, with $9000.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Other Non-Current Assets changed 0.0% year-over-year to $9000.0; the TTM figure through Sep 2023 stood at $9000.0 (changed 0.0% YoY), while the FY2022 annual figure was $9000.0, changed N/A from the prior year.
- Other Non-Current Assets steadied at $9000.0 in Q3 2023 per GTBP's latest filing, from $9000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $84000.0 in Q3 2020 and bottomed at $9000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $15642.9 across 4 years, with a median of $10500.0 in 2019.
- Annual changes were most pronounced in 2019 — Other Non-Current Assets sank 42.86% — and 2020, when it jumped 600.0%.
- GT Biopharma's Other Non-Current Assets stood at $12000.0 in 2019, then surged by 600.0% to $84000.0 in 2020, then sank by 89.29% to $9000.0 in 2022, then changed by 0.0% to $9000.0 in 2023.
- Business Quant data shows GTBP's Other Non-Current Assets at $9000.0 in Q3 2023, $9000.0 in Q2 2023, and $9000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | 570,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 9,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | 9,000.00 |
| Sep 30, 2022 | 9,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Sep 30, 2020 | 84,000.00 |
| Jun 30, 2020 | 12,000.00 |
| Mar 31, 2020 | 12,000.00 |
| Dec 31, 2019 | 12,000.00 |
| Sep 30, 2019 | 12,000.00 |
| Jun 30, 2019 | 12,000.00 |
| Mar 31, 2019 | 12,000.00 |
| Dec 31, 2018 | 12,000.00 |
| Sep 30, 2018 | 21,000.00 |
| Jun 30, 2018 | 9,000.00 |
| Mar 31, 2018 | 9,000.00 |
| Dec 31, 2017 | 9,000.00 |
| Mar 31, 2014 | 5,000.00 |